Milligan Sandra — SEC insider filings
SEC reporting owner CIK 1859810. 27 insider filings on record with FilingPulse; latest filed 2026-09-25.
Transaction summary — filings shown
Covers all 27 filings on record, filed 2021-06-04 to 2026-09-25. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 2 filings — 58,050 shares, $75,229 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 59.
- Largest priced transaction: purchase of 26,050 shares @ $1.92 ($50,016) in Gossamer Bio, Inc., filed 2025-08-20.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | Director | 9 | 2 legs · 58,050 sh · $75,229 | — | 7 |
| Organon & Co. (OGN) | Head of Research & Development | 10 | — | — | 41 |
| Aspira Women's Health Inc. (AWH) | Interim CEO | 5 | — | — | 8 |
| Spyre Therapeutics, Inc. (SYRE) | Director | 3 | — | — | 3 |
Insider filings — Milligan Sandra
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-25 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 115,000 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | Spyre Therapeutics, Inc. (SYRE) | Grant/award (A): 8,026 (derivative) @ $0 | EDGAR |
| 2025-08-20 | 4 | Gossamer Bio, Inc. (GOSS) | Purchase (P): 26,050 @ $1.92 | EDGAR |
| 2025-06-26 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 115,000 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Spyre Therapeutics, Inc. (SYRE) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-01-29 | 4/A | Aspira Women's Health Inc. (AWH) | Option exercise (M): 20,000 @ $0 · Tax withholding (F): 6,356 @ $0.70 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2025-01-08 | 4 | Aspira Women's Health Inc. (AWH) | Option exercise (M): 20,000 @ $0 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2024-11-13 | 4 | Aspira Women's Health Inc. (AWH) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-10-28 | 4 | Aspira Women's Health Inc. (AWH) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2024-06-06 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 115,000 (derivative) @ $0 | EDGAR |
| 2024-05-16 | 4 | Spyre Therapeutics, Inc. (SYRE) | Grant/award (A): 21,980 (derivative) @ $0 | EDGAR |
| 2024-05-06 | 4 | Aspira Women's Health Inc. (AWH) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2023-11-17 | 4 | Gossamer Bio, Inc. (GOSS) | Purchase (P): 32,000 @ $0.79 | EDGAR |
| 2023-06-09 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2023-05-08 | 4 | Organon & Co. (OGN) | Option exercise (M): 4,984 · Tax withholding (F): 2,168 @ $24.24 · Option exercise (M): 4,984 (derivative) @ $0 | EDGAR |
| 2023-05-03 | 4 | Organon & Co. (OGN) | Option exercise (M): 1,899 · Tax withholding (F): 826 @ $24.63 · Option exercise (M): 1,899 (derivative) @ $0 | EDGAR |
| 2023-04-04 | 4 | Organon & Co. (OGN) | Option exercise (M): 5,964 @ $0 · Tax withholding (F): 2,115 @ $23.09 · Option exercise (M): 5,964 (derivative) @ $0 · Grant/award (A): 29,230 (derivative) @ $0 · Grant/award (A): 104,961 (derivative) @ $0 | EDGAR |
| 2023-03-02 | 4 | Organon & Co. (OGN) | Option exercise (M): 7,976 · Tax withholding (F): 2,346 @ $25.09 · Option exercise (M): 7,976 (derivative) @ $0 | EDGAR |
| 2022-07-15 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2022-05-05 | 4 | Organon & Co. (OGN) | Option exercise (M): 1,842 · Tax withholding (F): 525 @ $32.08 · Option exercise (M): 4,984 · Tax withholding (F): 1,806 @ $32.44 · Option exercise (M): 1,842 (derivative) @ $0 · Option exercise (M): 4,984 (derivative) @ $0 | EDGAR |
| 2022-05-03 | 4 | Organon & Co. (OGN) | Option exercise (M): 1,896 · Tax withholding (F): 540 @ $32.33 · Option exercise (M): 1,896 (derivative) @ $0 | EDGAR |
| 2022-04-04 | 4 | Organon & Co. (OGN) | Grant/award (A): 17,892 (derivative) @ $0 · Grant/award (A): 55,114 (derivative) @ $0 | EDGAR |
| 2022-03-02 | 4 | Organon & Co. (OGN) | Option exercise (M): 10,171 · Tax withholding (F): 2,941 @ $37.57 · Option exercise (M): 10,171 (derivative) @ $0 | EDGAR |
| 2021-08-19 | 4 | Organon & Co. (OGN) | Grant/award (A): 22,321 (derivative) @ $0 | EDGAR |
| 2021-06-14 | 4 | Gossamer Bio, Inc. (GOSS) | Grant/award (A): 47,000 (derivative) @ $0 | EDGAR |
| 2021-06-04 | 4 | Organon & Co. (OGN) | Grant/award (A): 1,842 (derivative) @ $0 · Grant/award (A): 3,795 (derivative) @ $0 · Grant/award (A): 14,957 (derivative) @ $0 · Grant/award (A): 10,170 (derivative) @ $0 · Grant/award (A): 7,975 (derivative) @ $0 · Grant/award (A): 19,828 (derivative) @ $0 · +6 more | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-06-03 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1859810 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs